Key result
Hyperlipidemia and hypercholesterolemia in men are linked to elevated 11-dehydrothromboxane B2 excretion versus normolipidemic controls.
Why the study?
Does combined hyperlipidemia or isolated hypercholesterolemia increase platelet activity in vivo compared to normolipidemic controls?
Observational (n=91)
Does combined hyperlipidemia or isolated hypercholesterolemia increase platelet activity in vivo compared to normolipidemic controls?
Answers are grounded in this paper and cite their sources.
Thromboxane generation and platelet secretion in vivo are enhanced in patients with hypercholesterolemia, particularly those with concomitant elevation of plasma triglycerides, suggesting a mechanism for increased coronary risk.
Platelet hyperactivity in vitro is found in patients with isolated hypercholesterolemia. It is, however, less well established if platelet activity in vivo is enhanced, and if there are differences between various types of hyperlipoproteinemia. Platelet function in vivo was studied at rest and during mental stress in men with isolated hypercholesterolemia (phenotype IIa; n = 21) or combined hyperlipidemia (phenotype IIb; n = 29), and age-matched normolipidemic controls (n = 41). The urinary excretion of 11-dehydrothromboxane B2 was elevated in patients compared to controls (IIa, p <0.05; IIb, p <0.001), and higher in type IIb than in IIa patients (p <0.05). Platelet secretion, assessed as plasma beta-thromboglobulin levels, was higher in type IIb patients compared to controls (p <0.01) and type IIa patients (p <0.05) during mental stress. The urinary excretion of beta-thromboglobulin was also elevated in type IIb patients compared to controls (p <0.05). Platelet aggregability at rest, as measured by filtragometry ex vivo was, however, reduced in both patient groups compared to controls (p <0.05). No correlations were found between plasma lipoprotein levels and markers of platelet function in vivo. Type IIb patients had higher plasma fibrinogen levels and higher leukocyte counts than controls (p <0.05 and p <0.001) and type IIa patients (p <0.05 and p = 0.06). Thromboxane excretion was positively related to fibrinogen levels and leukocyte counts (p <0.01 for both). Preliminary data regarding serum TNF-alpha also indicated an elevation of this inflammatory cytokine in type IIb patients (p <0.05 vs controls). In conclusion, thromboxane generation and platelet secretion in vivo are enhanced in patients with hypercholesterolemia, and particularly so among patients with concomitant elevation of plasma triglycerides. The mechanism is unknown, but inflammatory mediators may be involved. The present findings are of interest in relation to the role of triglycerides in coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Bröijersén et al. (1998) conducted an observational in Hyperlipoproteinemia (n=91). Hyperlipoproteinemia (phenotype IIa and IIb) vs. Normolipidemic controls was evaluated on Urinary excretion of 11-dehydrothromboxane B2 (p=<0.001). Combined hyperlipidemia and isolated hypercholesterolemia in men were associated with elevated urinary excretion of 11-dehydrothromboxane B2 compared to normolipidemic controls (p<0.001 and p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: